

## (51) International Patent Classification:

A61K 39/095 (2006.01) C07K 14/22 (2006.01)

C07K 16/12 (2006.01)

## (21) International Application Number:

PCT/IB2013/051791

## (22) International Filing Date:

6 March 2013 (06.03.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/609,257 9 March 2012 (09.03.2012) US

## (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

## (72) Inventors: ANDERSON, Annaliesa Sybil; 49 Hillcrest Drive, Upper Saddle River, New Jersey 07458 (US). HOISETH, Susan Kay; 17 Coe Farm Road, Montebello, New York 10901 (US). JANSEN, Kathrin Ute; 57 Heather Court, Allendale, New Jersey 07401 (US). MORAN, Justin Keith; 682 Sierra Vista Lane, Valley Cottage, New York 10989 (US). RUPPEN, Mark E.; 6 Lea Court, Garnerville, New York 10923 (US).

## (74) Agent: KLEIMAN, Gabriel L.; Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US).

## (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

## (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

## Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

## (88) Date of publication of the international search report:

9 January 2014

## (54) Title: NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF

FIG. 9A

|           |      |                                                              |  |     |
|-----------|------|--------------------------------------------------------------|--|-----|
|           |      | 1                                                            |  | 60  |
| A05       | (1)  | CSSGSGSGGGVAAADIGTGLADALTAPLDHKDKGLKSLTLESGFQYKQDHSALVALQTEK |  |     |
| A12       | (1)  | CSSG---GGVAAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLKLAQAQGAET  |  |     |
| A22       | (1)  | CSSG---GGVAAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLKLAQAQGAET  |  |     |
| A62       | (1)  | CSSG---GGVAAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLKLAQAQGAET  |  |     |
| B09       | (1)  | CSSG---GGVAAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLKLAQAQGAET  |  |     |
| B24       | (1)  | CSSG---GGVAAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLKLAQAQGAET  |  |     |
| Consensus | (1)  | CSSG GGVAAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLKLAQAQGAET    |  |     |
|           |      | 61                                                           |  | 120 |
| A05       | (61) | SKVGDKNLSLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQYKQDHSALVALQTEK  |  |     |
| A12       | (57) | YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQYKQDHSALVALQTEK  |  |     |
| A22       | (57) | YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQYKQDHSALVALQTEK  |  |     |
| A62       | (57) | YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQYKQDHSALVALQTEK  |  |     |
| B09       | (57) | YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQYKQDHSALVALQTEK  |  |     |
| B24       | (57) | YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQYKQDHSALVALQTEK  |  |     |
| Consensus | (61) | YGNGD SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQYKQDHSALVALQTEK    |  |     |

(57) Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from *Neisseria meningitidis* serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.